UK markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.9935-0.0265 (-2.60%)
As of 12:58PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 127.18M
Enterprise value 33.15M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.29
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.09

Trading information

Stock price history

Beta (5Y monthly) 1.15
52-week change 336.00%
S&P500 52-week change 328.14%
52-week high 31.3900
52-week low 30.5900
50-day moving average 30.8700
200-day moving average 30.8613

Share statistics

Avg vol (3-month) 3420.69k
Avg vol (10-day) 3484.78k
Shares outstanding 5125.3M
Implied shares outstanding 6125.3M
Float 8117.5M
% held by insiders 10.04%
% held by institutions 113.06%
Shares short (31 Jan 2024) 46.84M
Short ratio (31 Jan 2024) 418.59
Short % of float (31 Jan 2024) 45.46%
Short % of shares outstanding (31 Jan 2024) 45.46%
Shares short (prior month 29 Dec 2023) 46.36M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 320 Apr 2018
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 320 Apr 2018

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-16.69%
Return on equity (ttm)-26.86%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -30.48M
Net income avi to common (ttm)-29.83M
Diluted EPS (ttm)-0.2400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)94.03M
Total cash per share (mrq)0.75
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)28.35
Book value per share (mrq)0.78

Cash flow statement

Operating cash flow (ttm)-19.89M
Levered free cash flow (ttm)-10.44M